- Home
- INBS vs BCDA Comparison
INBS vs BCDA Comparison
Compare INBS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- BCDA
- Stock Information
- Founded
- INBS 2016
- BCDA N/A
- Country
- INBS United States
- BCDA United States
- Employees
- INBS N/A
- BCDA N/A
- Industry
- INBS Medical Specialities
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- INBS Health Care
- BCDA Health Care
- Exchange
- INBS Nasdaq
- BCDA Nasdaq
- Market Cap
- INBS 8.7M
- BCDA 9.4M
- IPO Year
- INBS N/A
- BCDA N/A
- Fundamental
- Price
- INBS $1.24
- BCDA $2.32
- Analyst Decision
- INBS
- BCDA Strong Buy
- Analyst Count
- INBS 0
- BCDA 1
- Target Price
- INBS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- INBS 113.6K
- BCDA 102.2K
- Earning Date
- INBS 05-13-2025
- BCDA 05-14-2025
- Dividend Yield
- INBS N/A
- BCDA N/A
- EPS Growth
- INBS N/A
- BCDA N/A
- EPS
- INBS N/A
- BCDA N/A
- Revenue
- INBS $2,936,472.00
- BCDA $58,000.00
- Revenue This Year
- INBS $280.88
- BCDA N/A
- Revenue Next Year
- INBS $126.26
- BCDA N/A
- P/E Ratio
- INBS N/A
- BCDA N/A
- Revenue Growth
- INBS 3.87
- BCDA N/A
- 52 Week Low
- INBS $1.00
- BCDA $1.63
- 52 Week High
- INBS $3.04
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- INBS 43.94
- BCDA 45.74
- Support Level
- INBS $1.16
- BCDA $2.40
- Resistance Level
- INBS $1.43
- BCDA $2.92
- Average True Range (ATR)
- INBS 0.10
- BCDA 0.31
- MACD
- INBS 0.02
- BCDA -0.00
- Stochastic Oscillator
- INBS 42.42
- BCDA 9.28
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).